[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351575-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351575-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","btg3-suppresses-oral-squamous-cell-carcinoma-progression-by-inhibiting-pi3kakt-signaling-and-emt","BTG3 suppresses oral squamous cell carcinoma progression by inhibiting PI3K/AKT signaling and EMT","","B-cell translocation gene 3 (BTG3) is a tumor suppressor reduced in several cancers, but its function in oral squamous cell carcinoma (OSCC) remains unclear. This study evaluated BTG3 expression in OSCC and normal tissues using GEO and survival analysis from Kaplan-Meier Plotter. Molecular assays including western blotting and qRT-PCR were complemented by cell-based gain- and loss-of-function experiments, showing that BTG3 overexpression curbed proliferation, migration, invasion, and EMT progression via PI3K/AKT inhibition, while knockdown produced opposite effects. BTG3 is proposed as a therapeutic target in OSCC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/btg3-suppresses-oral-squamous-cell-carcinoma-progression-by-inhibiting-pi3kakt-signaling-and-emt/351575/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/btg3-suppresses-oral-squamous-cell-carcinoma-progression-by-inhibiting-pi3kakt-signaling-and-emt/351575.png","ImageObject",300,407,{"name":42,"@type":43},"Putri","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was BTG3 expression evaluated in OSCC tissues and normal tissues?","Question",{"text":63,"@type":64},"BTG3 levels in OSCC and normal tissues were analyzed using the GEO database and confirmed with western blotting and quantitative real-time PCR in OSCC tissues and neighboring normal tissues.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What cellular effects occur when BTG3 is overexpressed or knocked down?",{"text":68,"@type":64},"Overexpression of BTG3 inhibited OSCC cell proliferation, migration, and invasion and caused G1 phase cell-cycle arrest, while BTG3 knockdown produced opposite effects.",{"name":70,"@type":61,"acceptedAnswer":71},"How does BTG3 influence PI3K/AKT signaling and EMT progression?",{"text":72,"@type":64},"BTG3 overexpression negatively regulated the PI3K/AKT signaling pathway and inhibited EMT progression; the reverse effect was observed after BTG3 knockdown.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351575,1790817427,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nBTG3 suppresses oral squamous cell carcinoma progression by inhibiting PI3K/AKT signaling and EMT  \nSu Zhang, Xi Chen, Zhuang Liang, Wei Wang & Tenglong Hu􀀍  \nB-cell translocation gene 3 (BTG3), a tumor suppressor, is reduced in expression in several malignancies, including ovarian cancer, colorectal cancer, and gastric cancer, but its role in oralsquamous cell carcinoma (OSCC) is unknown. This study aimed to investigate the expression of BTG3 in OSCC, as well as explore its impact on the biological behavior of OSCC and the potential regulatory mechanisms. BTG3 expression levels inOSCC and normal tissues were examined using the GEO database and the Kaplan-Meier Plotter database was used for survival analysis. Western blotting and quantitative real-time PCR were used to assess BTG3 expression levels in OSCC tissues and neighboring normal tissues, as well as in oral epithelial cells (HOEC) and OSCC cell lines (CAL27 and SCC15). We found the expression level of BTG3 was lower in OSCC tissues than in surrounding normal tissues, with higher expression indicating a better prognosis. In vitro assay demonstrated that overexpression of BTG3 inhibited OSCC cell proliferation, migration, and invasion, resulting in cell cycle arrest at the G1 phase, as well as negatively regulating the PI3K/AKT signaling pathway and inhibiting EMT progression; knockdown had the opposite effect. BTG3 represents a potential therapeutic target in OSCC treatment.  \nKeywords BTG3, Oral squamous cell carcinoma, PI3K/AKT, EMT  \nOral squamous cell carcinoma (OSCC) is the most common cancer among head and neck malignancies worldwide, accounting for more than 90% of all cancers1. OSCC can be caused by a variety of etiologies, with smoking and alcohol intake being two of the most prominent risk factors2, which work together to make the oral epithelium more permeable, raising the risk of OSCC3. Although therapies for OSCC are improving, patients are diagnosed at an advanced stage and usually show a tendency to lymph node metastasis due to their lack of early symptoms, resulting in a low 5-year survival rate of 50%4. Patients are in poor condition5 and frequently have recurrence or a second primary tumor as a result of local carcinoma6. Therefore, it is still important to study the pathogenesis ofOSCC and find its potential therapeutic targets. In recent years, researches into OSCC have delved into molecular levels such as the tumor microenvironment7, immune infiltration8, and epithelialmesenchymal transition (EMT) regulation9. Concurrently, novel therapeutic approaches like phage therapy have demonstrated potential10. This underscores the urgency of exploring key regulatory molecules in OSCC from multiple perspectives.  \nB-cell translocation gene3 (BTG3) is a member of the B-cell translocation gene (BTG)/transducer of the ErbB2 (Tob) family, which also includes BTG1, BTG2, BTG4, Tob1, and Tob211. All members of the family share a conserved N-terminal structural domain spanning 104–106 amino acids and a variable C-terminal structural domain12. Overexpression of BTG/Tob proteins not only inhibits cell proliferation, but also regulates differentiation and cell cycle progression in a variety of cell types13, which is mainly mediated by their conserved N-terminal structural domain14. E2F1 is an important transcription factor that regulates cell entry into the S phase, and BTG3 can interact with it and inhibit its activity, thereby suppressing cell proliferation15. Previous studies have shown that BTG3 expression is down-regulated in a variety of malignant tumors, including ovarian cancer12, colorectal cancer16, esophageal adenocarcinoma17, gastric cancer18, lung cancer19, and prostate cancer20, whereas its role in OSCC is unknown.  \nDepartment of Oral and Maxillofacial Surgery, School ofStomatology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China.","cbCaiitDgpqr14E9","https://ap.wps.com/l/cbCaiitDgpqr14E9","pdf",2382179,12,"English","# Background\n## OSCC risk factors and prognosis\n## BTG/Tob family and BTG3 role\n# Mechanisms and rationale\n## Cell migration, invasion, and EMT\n# Methods and experimental approach\n## Expression analysis and survival assessment\n## Protein and gene expression assays\n## Cell functional assays\n# Results\n## BTG3 is lowly expressed in OSCC","[{\"question\":\"How was BTG3 expression evaluated in OSCC tissues and normal tissues?\",\"answer\":\"BTG3 levels in OSCC and normal tissues were analyzed using the GEO database and confirmed with western blotting and quantitative real-time PCR in OSCC tissues and neighboring normal tissues.\"},{\"question\":\"What cellular effects occur when BTG3 is overexpressed or knocked down?\",\"answer\":\"Overexpression of BTG3 inhibited OSCC cell proliferation, migration, and invasion and caused G1 phase cell-cycle arrest, while BTG3 knockdown produced opposite effects.\"},{\"question\":\"How does BTG3 influence PI3K/AKT signaling and EMT progression?\",\"answer\":\"BTG3 overexpression negatively regulated the PI3K/AKT signaling pathway and inhibited EMT progression; the reverse effect was observed after BTG3 knockdown.\"}]","BTG3 suppresses oral squamous cell carcinoma progression by inhibiting PI3K/AKT signaling and EMT | PDF",1790094769,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a05dfe7f7e65d9e0ee0be0e8f0be3cd.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bc25785fe48ac813816d1b86f6c4047.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d86823f2a77d34f4d753e1050603ebac.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a15c01f33e630bcdfc0022c572f14322.webp",980,1287]